The nine different antimitochondrial antibody specificities found in non-hepatic and hepatic disorders are described. Anti-M1 and anti-M7 antibodies are associated with infectious disorders such as syphilis or myocarditis. Anti-M3 and anti-M6 have been found in the course of a drug allergic disease due to Venocuran and iproniazid, and anti-M5 antibodies seem to occur occasionally in some forms of ANA-positive and ANA-negative collagen disorders. The M1- and M7-antigens are biochemically defined as cardiolipin and sarcosine dehydrogenase, respectively. Anti-M2, anti-M4, anti-M8, anti-M9 are associated with primary biliary cirrhosis (PBC). M2 was identified as α-ketoacid-dehydrogenase complex of the inner mitochondrial membrane, anti-M4 as sulfite oxidase, an enzyme of the mitochondrial intermembrane space, and anti-M9 as glycogen phosphorylase, a cytoplasmic enzyme. M8 copurifies with outer mitochondrial membranes derived from pig kidney. Anti-M9 can occur in the absence of anti-M2 while anti-M4 and anti-M8 are always associated with anti-M2. A progressive course of PBC can be predicted with high probability even at early stages of the disease when complement fixing antibodies against M2, M4 and/or M8 are present in patients’ sera. In contrast, the presence of anti-M2/M9 antibodies heralds a benign course. The etiopathogenesis of PBC is still unknown. In PBC contact persons a strong stimulation of naturally occurring mitochondrial antibodies (NOMA) has been observed which was in contrast to the lack of this antibody type in PBC patients. Considering the generally accepted role of those antibodies in protecting individuals from infections, the failure of NOMA production may be a predisposing factor to acquire PBC more easily.
Prof. Dr. P. A. Berg, Department of Internal Medicine, University of Tübingen, Otfried-Müller-Strasse, D-W-7400 Tübingen (FRG)
Published online: November 04, 2008
Number of Print Pages : 17
Digestive Diseases (Clinical Reviews)
Vol. 10, No. 2, Year 1992 (Cover Date: 1992)
Journal Editor: Malfertheiner P. (Magdeburg)
ISSN: 0257–2753 (Print), eISSN: 1421–9875 (Online)
For additional information: http://www.karger.com/DDI
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.